Merrimack Pharmaceuticals, Inc, announced that the FDA has granted MM-398 orphan drug status for the treatment of pancreatic cancer. MM-398 is a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. MM-398 is partnered with PharmaEngine, Inc, for development and commercialization in Taiwan under the designation PEP02.
Merrimack is a biopharmaceutical company discovering, developing, and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases. Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by the end of 2011. ■